The global artemisinin market size was estimated to be USD 96.1 million in 2023 and is expected to reach USD 677.9 million by 2034 with a CAGR of 19.43% during the forecast period 2024-2034. The rising burden of malaria, increased access to artemisinin-based combination therapies, growing awareness of the benefits of artemisinin, research, and development into new artemisinin-based treatments, and government support for malaria control will drive the market growth.
ACTs are the first-line treatment for malaria recommended by the WHO. They combine artemisinin with other antimalarial drugs, making it more difficult for the parasites to develop resistance. Access to ACTs has increased significantly in recent years, thanks to initiatives such as the Affordable Medicines Facility for Malaria (AMFm) and the President's Malaria Initiative (PMI). For instance, in November 2023, Artemis International Inc., in partnership with the Kenyan Agricultural Research and Livestock Organization, introduced a new, high-yielding cultivar of Artemisia Annua. obtained a grant of USD 5 million from USAID for projects about sustainable production.
By type, the extraction from the artemisia annua segment accounted for the highest revenue-grossing segment in the global artemisinin market in 2023 owing to the primary source of artemisinin, with pharmaceutical companies relying on a consistent and high-quality supply to meet the increasing global need for effective and life-saving anti-malarial medications. For instance, KPC Pharmaceuticals, Inc. introduced Artesunyl IV, a novel long-acting injectable artesunate, in December 2023 to treat severe malaria. obtained Indonesian regulatory clearance for Artesunate-Mefloquine pills. Additionally, the semisynthetic artemisinin segment is predicted to grow at the fastest CAGR during the forecast period owing to the advancements in pharmaceutical research and development, which have led to the synthesis of semisynthetic artemisinin with enhanced properties and improved scalability.
By application, the antimalarial tablets segment accounted for the highest revenue-grossing segment in the global artemisinin market in 2023 owing to the growing prevalence of malaria worldwide and the widespread adoption of artemisinin-based combination therapies (ACTs) encapsulated in antimalarial tablets. For instance, Guilin Pharmaceutical Co., Ltd. increased its manufacturing capacity by 20% in October 2023 in response to growing demand. invested in the development of innovative antimalarials based on artemisinin for non-falciparum malaria. Additionally, the antimalarial injections segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for rapid and potent treatment options, particularly in severe malaria cases, where the prompt administration of artemisinin-based therapies is critical.
By distribution channel, the hospital pharmacy segment accounted for the highest revenue-grossing segment in the global Artemisinin market in 2023 owing to the increasing number of cochlear implant surgeries performed in hospital settings and the rising prevalence of hearing impairment globally. For instance, Kunming Pharmaceutical Corporation exceeded its yearly target in September 2023 and achieved record output of semisynthetic artemisinin. working together with academic institutions to increase the synthesis process's cost-effectiveness. Additionally, the online pharmacy segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing trend of digitalization in healthcare services, increased consumer preference for online shopping, and the convenience offered by online pharmacies in providing a wide range of pharmaceutical products, including cochlear implants.
North American region is anticipated to have the highest revenue share during the forecast period owing to the presence of a well-established healthcare infrastructure, increasing prevalence of hearing disorders, high adoption of advanced medical technologies, and a robust reimbursement framework. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising awareness of hearing impairment, increasing healthcare investments, expanding patient population, and improving accessibility to advanced medical treatments. For instance, the KERUI Group completed the Phase II clinical study for a new oral artemisinin derivative that acts as a long-acting malaria preventive agent in August 2023. landed a $25 million investment for clinical development in the latter stages.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
ACTs are the first-line treatment for malaria recommended by the WHO. They combine artemisinin with other antimalarial drugs, making it more difficult for the parasites to develop resistance. Access to ACTs has increased significantly in recent years, thanks to initiatives such as the Affordable Medicines Facility for Malaria (AMFm) and the President's Malaria Initiative (PMI). For instance, in November 2023, Artemis International Inc., in partnership with the Kenyan Agricultural Research and Livestock Organization, introduced a new, high-yielding cultivar of Artemisia Annua. obtained a grant of USD 5 million from USAID for projects about sustainable production.
By type, the extraction from the artemisia annua segment accounted for the highest revenue-grossing segment in the global artemisinin market in 2023 owing to the primary source of artemisinin, with pharmaceutical companies relying on a consistent and high-quality supply to meet the increasing global need for effective and life-saving anti-malarial medications. For instance, KPC Pharmaceuticals, Inc. introduced Artesunyl IV, a novel long-acting injectable artesunate, in December 2023 to treat severe malaria. obtained Indonesian regulatory clearance for Artesunate-Mefloquine pills. Additionally, the semisynthetic artemisinin segment is predicted to grow at the fastest CAGR during the forecast period owing to the advancements in pharmaceutical research and development, which have led to the synthesis of semisynthetic artemisinin with enhanced properties and improved scalability.
By application, the antimalarial tablets segment accounted for the highest revenue-grossing segment in the global artemisinin market in 2023 owing to the growing prevalence of malaria worldwide and the widespread adoption of artemisinin-based combination therapies (ACTs) encapsulated in antimalarial tablets. For instance, Guilin Pharmaceutical Co., Ltd. increased its manufacturing capacity by 20% in October 2023 in response to growing demand. invested in the development of innovative antimalarials based on artemisinin for non-falciparum malaria. Additionally, the antimalarial injections segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for rapid and potent treatment options, particularly in severe malaria cases, where the prompt administration of artemisinin-based therapies is critical.
By distribution channel, the hospital pharmacy segment accounted for the highest revenue-grossing segment in the global Artemisinin market in 2023 owing to the increasing number of cochlear implant surgeries performed in hospital settings and the rising prevalence of hearing impairment globally. For instance, Kunming Pharmaceutical Corporation exceeded its yearly target in September 2023 and achieved record output of semisynthetic artemisinin. working together with academic institutions to increase the synthesis process's cost-effectiveness. Additionally, the online pharmacy segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing trend of digitalization in healthcare services, increased consumer preference for online shopping, and the convenience offered by online pharmacies in providing a wide range of pharmaceutical products, including cochlear implants.
North American region is anticipated to have the highest revenue share during the forecast period owing to the presence of a well-established healthcare infrastructure, increasing prevalence of hearing disorders, high adoption of advanced medical technologies, and a robust reimbursement framework. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising awareness of hearing impairment, increasing healthcare investments, expanding patient population, and improving accessibility to advanced medical treatments. For instance, the KERUI Group completed the Phase II clinical study for a new oral artemisinin derivative that acts as a long-acting malaria preventive agent in August 2023. landed a $25 million investment for clinical development in the latter stages.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Type, Application, and Distribution Channel
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Artemisinin Market Report 2023 - 2034
Artemisinin Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Mn)
- Extraction from Artemisia Annua
- Semisynthetic Artemisinin
Artemisinin Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Mn)
- Antimalarial Injections
- Antimalarial Tablets
Artemisinin Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Mn)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Artemisinin Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Mn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Artemisinin Market: Type Estimates & Trend Analysis
8. Artemisinin Market: Application Estimates & Trend Analysis
9. Artemisinin Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Artemisinin Market
12. Europe Global Artemisinin Market
13. Asia Pacific Global Artemisinin Market
14. Latin America Global Artemisinin Market
15. MEA Global Artemisinin Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Sanofi S.A.
- Artemis International Inc.
- KPC Pharmaceuticals Inc.
- Guilin Pharmaceutical Co. Ltd.
- Kunming Pharmaceutical Corporation
- KERUI Group (Artemisinin Biotech)
- Phytomedics Inc.
- Natural Remedies Pvt. Ltd.
- AIFLINC
- Alchem International Pvt Ltd.
- Sanmark Corp.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 96.1 Million |
| Forecasted Market Value ( USD | $ 677.9 Million |
| Compound Annual Growth Rate | 19.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
